Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE MySkin, Inc.
DENVER, April 30, 2014 /PRNewswire/ -- MySkin, Inc. (OTCQB: MYSK) MYSKIN, INC., a California corporation, which intends to change its name to United Cannabis Corporation, and shall be referred to herein as ("UCANN"), announced today it has entered into a management and investment agreement with a Nevada limited liability company (Nevco). Nevco, which has requested confidentiality as to its name while it is in the licensing process, is currently in the process of applying for a license to own and operate a registered and licensed medical marijuana dispensary, as defined by the Nevada Marijuana Laws, Nev. Rev. Stat. Section 453A.010 et seq. Nevco is developing distribution and retail lines and facilities that it represents are consistent with the research and production, growth and distribution and consulting and development objectives of UCANN.
UCANN has invested $60,000 (Ten thousand) into Nevco. UCANN intends on providing the following services and know how to Nevco: Retail operating procedures, nutrition methodologies, and a cannabinoid therapy program that utilizes the entire cannabis plant controlling specific cannabinoid ratios, accurate dosing, and multiple delivery methods. The intellectual property, technology and methodologies are being provided for the production and extraction of full plant cannabis into individualized cannabinoid based products with medical applications focused on sublingual, dietary, inhalation, transdermal and drop delivery systems.
UCANN is a biotech company with a foundation built in the medical cannabis industry. It has over 200 hybrid strains designed to provide treatment to a wide variety of patients. It plans to partner domestically and internationally with local businessmen, entrepreneurs, scientists and government agencies for the purpose of consulting and providing guidance on design and construction of growth facilities and cultivation of medical grade cannabis-based products worldwide.
Neither the Company nor its employees will touch or handle the plants directly. The partners and their employees will be the handlers of the plants and products. The Company will not harvest, distribute or sell cannabis or any related substances that violate United States law or the Controlled Substances Act, nor does it intend to do so in the future.
Forward Looking Information
MySkin believes the information set forth in this Press Release may include "forward looking information" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Certain factors that could cause results to differ materially from those projected in the forward-looking statements are set forth in "Risk Factors" in Part I, Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2013, which was filed with the Securities and Exchange Commission on February 18, 2014.
©2012 PR Newswire. All Rights Reserved.